Guggenheim

Netflix Stock 'Firing On All Cylinders': 10 Analysts React To Q4 Beat, Guidance, Price Increases
Constellation Energy: Will AI Power Surge Light Up Stock?
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Constellation Energy: Will AI Power Surge Light Up Stock?
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Disney Q4 Earnings Show 'A Lot To Like': Analyst Calls It 'High-Quality' Profit Growth Performer
8 Tesla Analysts Size Up Margins, FSD, Robotaxis, New EVs As Stock Tanks: 'The Realities Of Today Vs. The Dreams Of Tomorrow'

Guggenheim Recent News

Why ServiceNow Stock Is Down Monday
ServiceNow shares are trading lower Monday after Guggenheim analyst John Difucci downgraded ServiceNow from Neutral to Sell and announced a $640 price target on the stock. Here's a look at the details.
Tesla Energy Draws Attention, Praise From Analysts, With Potential AI Boom: 'Gaining Market Share Or The Entire Market Is Growing Dramatically In 2024'
Tesla is known best for its electric vehicles. Analysts may be shifting attention to the company's energy storage business after a record Q2.
DOJ Case Against Live Nation Is 'Weak,' Analysts Say: 'Separating Ticketmaster... Is Unlikely To Lower Ticket Prices'
The Department of Justice's antitrust case against Live Nation could be tough to prove according to two analysts.
Lucid Q4 Earnings Preview: All Eyes On Lower EV Production, Delivery Guidance
Lucid stock is down 65% in the last year. A look at key items to watch for the company's fourth quarter financial results.
Meta Platforms Analysts Raise Expectations After Q4 Earnings Beat: 'Growth, Profits, Buyback & Dividends All In One'
Meta Platform shares hit 52-week highs after reporting Q4 results. Analysts see advertising strength, AI growth, and raise price targets.
Why Snap Shares Are Trending Higher Monday
Snap Inc. (NYSE: SNAP) shares are trading higher on Monday after Guggenheim upgraded the stock. Here's what investors need to know.  
Grunt Work No-More? Wokelo.AI Streamlines Due Diligence, Cut Costs, Automates 40% Of Tasks
When you're a young professional navigating the world of investment banking or private equity, the early days are typically filled with tedious tasks.
ESPN Bet Launches In 17 States, Offers $200 In Bonus Bets: Could Competition Spell Trouble For DraftKings?
ESPN Bet is offering $200 in bonus bets for users in 17 states. The launch could provide competition for market leaders like DraftKings.
Netflix Rallies Off Q3 Earnings: 8 Analysts On Future Price Increases, Ad-Supported Plans And More
Streaming giant Netflix Inc (NASDAQ: NFLX) reported third-quarter financial results after the mark
Tesla Sized Up By 9 Analysts After Q3 Earnings: 'Mini Disaster' Conference Call, First Bad Miss In Some Time, A Win For The Bears
Electric vehicle leader Tesla Inc (NASDAQ: TSLA) reported third quarter financial results after market close Wednesday.
4 Reasons Why This Ralph Lauren Analyst Is Bullish: 'Lower Cotton, Freight Expenses'
Shares of Ralph Lauren Corp (NYSE: RL) Monday continued their upward trajectory, after the spike on Friday last week.
5 Analysts Mixed On Meta Platforms: Post-Q2 Valuation Boost, AI Growth, But Concerns Over 2023 Share Gains, Spending
Analysts are sizing up the second quarter financial results reported by Meta Platforms (NASDAQ: META) after market close Wednesday, includin
Netflix Q2 Earnings Preview: Earnings Estimates, Analyst Predictions And Key Concerns Like The Hollywood Strike
Streaming giant Netflix Inc (NASDAQ: NFLX) is set to report second-quarter financial results after market close Wednesday, July 19.
Tesla Rallies Off Q4 Earnings: This Item 'Was All Bulls Needed To Hear,' Analyst Says
Electric vehicle giant Tesla Inc (NASDAQ: TSLA) beat analyst estimates for both revenue and earnings per share in the fourth quarter.
9 Nike Analysts On Q2 Earnings Beat, Improving Inventory Trends, China: 'Decidedly Upbeat'
Nike Inc (NYSE: NKE) shares rallied Wednesday morning after the company reported shrinking margins but said inventory levels have improved slightly on a quarterly basis.
Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish'
Merck & Co. Inc. (NYSE: MRK) seems well positioned to surpass 2023 consensus estimates, driven by margin potential, according to Guggenheim. The Analyst: Seamus Fernandez upgraded the rating for Merck from Neutral to Buy, while establishing a price target of $104.
5 Kohl's Analysts On Bloated Inventory, Guidance Cut: 'Fundamentals Are Likely To Get Worse'
Kohl's Corporation (NYSE: KSS) shares are down 4% on Friday after the company cut its guidance and said inflation is eating into its sales growth.
Why This Teladoc Health Analyst Expects 25%-30% Revenue Growth
Teladoc Health Inc (NYSE: TDOC) is a market leader in digital services, and the breadth of its services is unmatched, according to Guggenheim. The Teladoc Health Analyst: Sandy Draper initiated coverage of Teladoc Health with a Buy rating and $96 price target.
Pinterest's Stock Continues On Downward Spiral: What's Next?
Pinterest Inc (NYSE: PINS) shares traded lower Tuesday following a downgrade from Guggenheim. Analyst Michael Morris downgraded the stock from a Buy to a Neutral rating and lowered the price target from $46 to $39. This pushed Pinterest further below a technical channel it traded in.
Guggenheim CIO Scott Minerd Regrets Not Investing In Shiba Inu: 'I Wish I'd Invested $100,000'
Scott Minerd, the chief investment officer at Guggenheim Partners, revealed that he regrets missing out on the Shiba Inu (CRYPTO: SHIB) rally.
Can DraftKings Keep Its Competitive Edge While Growing
The large online sports betting and iGaming markets has an analyst impressed with the opportunity for DraftKings to keep its competitive advantage and grow with the market.
Fintech Focus For March 9, 2021
Why Guggenheim Is Bullish On Passage Bio
Passage Bio Inc (NASDAQ: PASG) is leveraging the UPenn Gene Therapy Program to access compelling translational research and develop a range of differentiated adeno-associated virus gene therapies for rare central nervous system disorders, according to Guggenheim.
;

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved